Eye herpes affects roughly 1.5 million people worldwide each year, making it more common than most people expect. In developed countries, it is the leading infectious cause of corneal blindness. While those numbers sound alarming, the condition is still relatively rare on an individual level: only about 5 to 15 new cases occur per 100,000 people each year in the populations where it has been carefully tracked.
Incidence by the Numbers
The best long-term data comes from studies in Rochester, Minnesota and France. The Rochester studies, which span decades, found the rate of new cases rose from 8.4 to 11.8 per 100,000 people per year between the mid-20th century and the early 2000s. A French study found a slightly higher rate of 13.2 new cases per 100,000. When you add in people who have already had an episode and are experiencing a flare-up, the total jumps considerably: 20.7 per 100,000 in Rochester and 31.5 per 100,000 in France.
Globally, that translates to about 1.5 million episodes per year. Of those, roughly 40,000 result in severe vision loss or blindness in the affected eye. About 1 million of the yearly cases involve the surface layer of the cornea, which is the most common and generally the most treatable form.
Why the Virus Targets the Eye
Almost all eye herpes is caused by herpes simplex virus type 1 (HSV-1), the same virus behind cold sores. After an initial infection, usually in childhood or adolescence, the virus retreats into a cluster of nerve cells near the base of the skull called the trigeminal ganglion. It stays there for life in a dormant state, producing almost no detectable viral proteins.
Your immune system actively patrols this nerve cluster. Specialized immune cells park themselves right next to infected nerve cells and keep the virus in check without destroying the neurons. This is a surprisingly precise arrangement: these immune cells carry a molecular “brake” that prevents them from killing the nerve cells they’re guarding, even though they’re armed with the enzymes to do so. When this surveillance weakens, even temporarily, the virus can reactivate and travel along nerve fibers to the eye, the lips, or other areas supplied by those nerves.
Recurrence Is the Bigger Concern
For many people, a single episode of eye herpes resolves with treatment and never returns. But the recurrence rates climb steadily over time. After a first episode, the chance of a second one is about 27% within one year, 50% within five years, and 63% within 20 years. Each recurrence carries a risk of additional corneal scarring, which is why repeated flare-ups are the main driver of vision loss rather than any single episode.
Known triggers for reactivation include physical or emotional stress, fever, sun exposure, eye surgery, and anything that suppresses the immune system. Some people notice a pattern to their outbreaks, while others experience them unpredictably.
What Eye Herpes Looks and Feels Like
The most common form, called epithelial keratitis, affects the outermost layer of the cornea. It typically starts in one eye with redness, tearing, light sensitivity, and a gritty or burning sensation. Vision may become blurry. An eye doctor examining the cornea with a slit lamp will often see a distinctive branching ulcer on the surface, which is one of the most recognizable patterns in ophthalmology and makes diagnosis relatively straightforward.
Deeper forms of eye herpes can involve the middle layers of the cornea (stromal keratitis) or the inside lining of the eye. These are less common but more likely to cause lasting damage because they trigger an inflammatory response that can scar the cornea permanently. Some people also develop herpes on the eyelids or the white of the eye, which tends to be milder.
How It’s Treated
Surface-level eye herpes is treated with antiviral medication, either as pills or as a gel applied directly to the eye. Most episodes of straightforward corneal herpes heal within one to two weeks with treatment. The goal is to stop the virus from replicating before it causes significant damage to the cornea.
For people who experience frequent recurrences, a long-term low-dose antiviral taken daily can cut the recurrence rate roughly in half. This preventive approach is especially important for anyone who has already developed some corneal scarring, since each new episode risks further vision loss. In severe cases where scarring has already clouded the cornea, a corneal transplant may eventually be needed to restore sight.
Putting the Risk in Perspective
HSV-1, the virus responsible for nearly all eye herpes, is extremely widespread. Roughly half of adults in the United States carry it, and in many parts of the world the rate is higher. Yet only a small fraction of those people ever develop an eye infection. The virus reactivates in the eye rather than the lip in a minority of cases, and many people with oral herpes will never have an ocular episode at all.
That said, eye herpes is not vanishingly rare either. It is common enough that ophthalmologists see it regularly, and its cumulative impact is significant: it remains the top infectious cause of corneal blindness in developed countries. The combination of a very common underlying virus and a low but real chance of it reaching the eye means that while any individual’s risk is small, the condition affects a substantial number of people across the population.